Abstract: A device holder is provided for retaining an M.2 device to a printed circuit board. The device holder includes a standoff portion, a cover portion, and a strap configured to retain the standoff portion to the cover portion. The standoff portion is configured to be affixed to the printed circuit board and to provide a standoff upon which a first end of the M.2 device can be seated. The cover portion is configured, in an open position, to permit the insertion of a second end of the M.2 device into an M.2 connector, and, in a closed position, to retain the M.2 device to the standoff portion.

Abstract: Disclosed herein include methods and compositions for use in generating synthetic embryos. In some embodiments, the method comprises culturing stem cells that over-express at least one Cadherin.

Abstract: A hand mechanism (2) comprises a plurality of finger units. Each of the plurality finger units is equipped with a first finger link unit (211) including a fingertip, a first joint unit (22) provided at an end portion on a finger base side of the first finger link unit (211), a second finger link unit (212) connected to the first finger link unit (211) via the first joint unit (22), and a second joint unit (23) provided at an end portion on a finger base side of the second finger link unit (212). A suction mechanism (600) is provided on at least one predetermined finger unit of the plurality of finger units (21). The suction mechanism (600) is provided on a dorsal surface (216) of the first finger link unit (211) in a predetermined finger, and suctions and retains a target object by generating negative pressure.

Abstract: The application describes a method of treating pneumonia (e.g. COVID-19 pneumonia) in a patient comprising administering a weight-based intravenous dose of tocilizumab to the patient, wherein the weight-based dose is 8 mg/kg of tocilizumab. It also describes a method of treating pneumonia in a patient comprising administering an IL6 antagonist (e.g. an IL6 receptor antibody such as tocilizumab) to the patient in an amount effective to achieve a greater improvement in clinical outcome than standard of care (SOC) as measured on an ordinal scale of clinical status.

Abstract: The application describes a method of treating viral pneumonia in a patient comprising administering an effective amount of a combination of tocilizumab and remdesiver to the patient.

Abstract: A method of treating pneumonia in a patient is disclosed comprising administering an effective amount of an IL-6 antagonist to a patient identified as having elevated ferritin level. Also disclosed is a method of achieving an improved clinical response in a patient with pneumonia comprising: a. measuring ferritin level in the patient, and b. administering an effective amount of an IL-6 antagonist to the patient identified as having an elevated ferritin level. The improved clinical response achieved includes: no death by Day 28, not mechanically ventilated by Day 28 (wherein the patient was not mechanically ventilated at baseline), better ordinal score at Day 28, and/or reduced time to hospital discharge within 28 days, compared to the clinical response in a patient with pneumonia and ferritin level that is not elevated.

Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

Abstract: A method of preparing ammonium glyphosate suitable for preparation of water-soluble solid ammonium glyphosate formulation by an extraction with organic solvent in a gas-liquid-solid phase system, which comprises adding glyphosate and water into a reactor with a stirer, introducing ammonia to carry out the reaction, an aqueous solution of ammonium glyphosate is formed after the reaction is completed; adding a water-soluble organic solvent such as methanol and/or ethanol and/or methylal to decrease the solubility of the ammonium glyphosate in the system, thereby crystallizing out ammonium glyphosate; and filtering in suction or further oven-drying to obtain the solid ammonium glyphosate. The organic solvent may be recovered and reused by rectifying or distilling, the remainder residue may be returned to the reaction procedure or used in the preparation of the aqueous formulation of ammonium glyphosate.

Abstract: A method of preparing ammonium glyphosate suitable for preparation of water-soluble solid ammonium glyphosate formulation by an extraction with organic solvent in a gas-liquid-solid phase system, which comprises adding glyphosate and water into a reactor with a stirer, introducing ammonia to carry out the reaction, an aqueous solution of ammonium glyphosate is formed after the reaction is completed; adding a water-soluble organic solvent such as methanol and/or ethanol and/or methylal to decrease the solubility of the ammonium glyphosate in the system, thereby crystallizing out ammonium glyphosate; and filtering in suction or further oven-drying to obtain the solid ammonium glyphosate. The organic solvent may be recovered and reused by rectifying or distilling, the remainder residue may be returned to the reaction procedure or used in the preparation of the aqueous formulation of ammonium glyphosate.